# Nanobiotix S.A. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Nanobiotix S.A.). ## Overview Nanobiotix S.A. is a clinical-stage biotechnology company developing nanotechnology-based therapeutic candidates, with its core programs centered on oncology and additional platform applications in bioavailability, biodistribution, and central nervous system disorders. The company is headquartered in Paris, France, and has a U.S. subsidiary in Cambridge, Massachusetts, while its shares trade on Euronext Paris and Nasdaq. ## Products & services • NBTXR3 oncology product candidate • Physics-based nanotherapy platform • Bioavailability and biodistribution platform • Central nervous system nanotechnology platform • Patent portfolio covering multiple nanotech families - **Oncology product candidates** (70%) — Clinical-stage cancer therapies and related development programs, including NBTXR3. - **Platform technologies** (20%) — Nanotechnology platforms used to generate therapeutic candidates across multiple indications. - **Licensing and collaboration rights** (10%) — Rights and partner-supported development activities tied to collaborative programs. - NBTXR3 oncology product candidate - Physics-based nanotherapy platform - Bioavailability and biodistribution platform - Central nervous system nanotechnology platform - Patent portfolio covering multiple nanotech families ## Customers Nanobiotix does not sell a broad commercial product portfolio; its direct counterparts are typically pharmaceutical and biotechnology partners, academic research institutions, and clinical collaborators involved in drug development. The end beneficiaries are patients in oncology and other therapeutic areas, while partner organizations use the company’s platforms and candidates to advance clinical programs and potential future approvals. - **Pharmaceutical partners** (primary) — Companies collaborating on development, clinical testing, and potential commercialization of NBTXR3 and related assets. - **Academic medical centers** (secondary) — Research institutions and cancer centers that sponsor or conduct clinical studies using the company’s platforms. - **Clinical trial participants** (primary) — Patients enrolled in studies for oncology and other indications, enabling proof-of-concept and regulatory progress. - **Potential future licensees** (emerging) — Third parties that could adopt or monetize the company’s platform technologies in new indications. - Pharma and biotech partners advancing oncology programs - Academic medical centers running investigator studies - Clinical collaborators supporting trial execution - Future patients in cancer and other therapeutic areas - Potential licensees seeking nanotechnology platforms ## Geography Nanobiotix is headquartered in Paris and operates internationally through a U.S. subsidiary in Cambridge, Massachusetts. Its shares are listed in Europe and the United States, and its development model depends on cross-border clinical collaboration and regulatory pathways rather than manufacturing geography. - Headquartered in Paris, France - U.S. subsidiary in Cambridge, Massachusetts - Listed on Euronext Paris and Nasdaq - Clinical collaborations span multiple countries - No country revenue disclosure provided ## Strategy The company’s strategy is built around advancing NBTXR3 and extending its nanotechnology platforms through partnerships, sponsored studies, and broader indication coverage. This approach spreads development across multiple programs while leveraging external collaborators to expand the clinical and commercial potential of the platform. - **Advance NBTXR3 clinical development** (short-term) — Clinical progress is the main value driver for a late-stage biotechnology company and underpins future approval opportunities. - **Expand collaboration network** (medium-term) — Partnerships broaden trial reach, share development burden, and increase the number of indications being evaluated. - **Develop additional nanotechnology platforms** (medium-term) — Diversifying beyond a single lead asset can widen the company’s addressable opportunity and reduce reliance on one program. - Advance NBTXR3 through late-stage clinical development - Use collaborations to broaden indication coverage - Extend platform use beyond oncology - Protect and expand the patent portfolio - Support development through capital raises and partnerships ## Risks Nanobiotix faces the typical risks of a clinical-stage biotech company: trial failure, regulatory delays, partner dependence, and the need to fund development before any commercial revenue is established. Its press releases also highlight cash runway assumptions, making financing access and execution on study milestones important to the business model. - **Clinical development failure** [critical] — The company’s value depends on successful trial readouts and regulatory acceptance of NBTXR3 and related programs. - **Financing and cash runway risk** [high] — Development-stage biotechnology companies consume cash before product sales, and the company explicitly flags runway assumptions. - **Partner dependence** [high] — Clinical expansion relies on collaborators and sponsors, which can affect timing, scope, and prioritization of studies. - **Regulatory and approval risk** [high] — Even positive clinical data may not translate into approval without sufficient safety, efficacy, and manufacturing evidence. - Clinical trial outcomes may not support approval or label expansion - Partner and sponsor dependence can slow or reshape development - Cash runway depends on assumptions and financing access - Regulatory review can delay commercialization - Platform science may not translate across indications ## Accounting As a clinical-stage biotech company, Nanobiotix’s reported results are likely driven by R&D expense recognition, collaboration-related accounting, and capitalization judgments rather than product revenue. Investors should watch how clinical trial costs, upfront partner payments, and any milestone or licensing income are recognized because these items can shift reported results materially from period to period. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Collaboration and milestone accounting** — Can create uneven revenue and income recognition - **Share-based compensation** — Affects operating expenses and diluted share counts - R&D expense timing affects operating loss and cash burn - Collaboration income may depend on milestone achievement - Upfront payments require allocation and recognition judgments - Share-based compensation can materially affect reported expense - Intangible asset and patent-related judgments may matter --- *Last updated: 2026-09-28T12:13:23.388056+00:00*